Anti-VEGF × Anti-DLL4 Bispecific Antibody (NANO-L002)
Recombinant Anti-VEGF & Anti-DLL4 Bispecific Antibody (Bi-Single Domain Antibody) comprises two monomeric VH-like binding entities of different specificities that are fused to each other in a bivalent-bispecific manner.Bi-Single Domain Antibody is only consisted of the VHHs. The loss of light chain and constant fragment in bi-Single Domain Antibody does not eliminate their functional antigen-binding capacity, but even endows them non-substitutable advantage in application. This BsAb is capable of inhibiting signaling of their cognate factors and a combined blockade of them has a greater inhibitory efficacy compared with inhibition of either factor alone.It was designed for the treatment of diseases associated with VEGF-mediated vascular effects for generation.
Specifications
- Targets
- VEGF & DLL4
- Type
- Bi-Single Domain Antibody
- Expression Host
- CHO
- Species Reactivity
- Human
- Target 1
- VEGF
- Host
- Llama
- Target 2
- DLL4
- Host
- Llama
- Purity
- >95% judged by SDS-PAGE under reducing condition
- Applications
- FuncS, Promising therapeutic agent
- Related Disease
- Central nervous system derived tumors
Targets
- Target 1
- VEGF
- Gene ID
- 7422
- UniProt ID
- P15692
- Alternative Names
- VEGFA; vascular endothelial growth factor A; VPF; VEGF; MVCD1; vascular permeability factor
- Target 2
- DLL4
- Gene ID
- 54567
- UniProt ID
- Q9NR61
- Alternative Names
- DLL4; delta-like 4 (Drosophila); hdelta2; delta-like protein 4; delta4; delta 4; delta ligand 4; notch ligand DLL4; delta-like 4 homolog; delta-like 4 protein; notch ligand delta-2; drosophila Delta homolog 4
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: